EOLS

NEW: Premarket Now Starts at 4AM!

We’re excited to announce the extension of premarket and aftermarket hours! Our members now have access to quotes daily from 4:00 AM to 8:00 PM ET — offering greater flexibility and deeper insights into market trends beyond regular trading hours.

Upgrade to FINVIZ*Elite to access premarket quotes »

Dollar change -0.30
Percentage change -3.00	%

Peers: ABBV LLY PFE AMGN BMY RVNC MRK TEVA PRGO PRPH

| Held by: VTI IWM VXF IWO VTWO SCHA VHT XPH IHE IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-0.89	Insider Own	11.76%	Shs Outstand	64.45M	Perf Week	-1.02%
Market Cap	625.41M	Forward P/E	16.77	EPS next Y	0.58	Insider Trans	-2.62%	Shs Float	56.92M	Perf Month	-4.06%
Income	-56.20M	PEG	-	EPS next Q	-0.09	Inst Own	84.40%	Short Float	15.35%	Perf Quarter	-34.19%
Sales	275.46M	P/S	2.27	EPS this Y	24.40%	Inst Trans	8.63%	Short Ratio	9.86	Perf Half Y	-22.03%
Book/sh	-0.10	P/B	-	EPS next Y	404.75%	ROA	-25.57%	Short Interest	8.74M	Perf Year	-24.04%
Cash/sh	1.05	P/C	9.21	EPS next 5Y	-	ROE	-949.46%	52W Range	8.67 - 17.82	Perf YTD	-12.14%
Dividend Est.	-	P/FCF	-	EPS past 5Y	23.91%	ROI	-46.21%	52W High	-45.57%	Beta	1.03
Dividend TTM	-	Quick Ratio	2.16	Sales past 5Y	51.00%	Gross Margin	66.43%	52W Low	11.88%	ATR (14)	0.69
Dividend Ex-Date	-	Current Ratio	2.34	EPS Y/Y TTM	15.00%	Oper. Margin	-13.02%	RSI (14)	36.64	Volatility	5.23% 5.76%
Employees	332	Debt/Eq	-	Sales Y/Y TTM	25.38%	Profit Margin	-20.40%	Recom	1.00	Target Price	23.57
Option/Short	Yes / Yes	LT Debt/Eq	-	EPS Q/Q	-33.00%	Payout	-	Rel Volume	1.45	Prev Close	10.00
Sales Surprise	-5.31%	EPS Surprise	-5.39%	Sales Q/Q	15.49%	Earnings	May 07 AMC	Avg Volume	886.30K	Price	9.70
SMA20	-11.21%	SMA50	-15.57%	SMA200	-27.83%	Trades		Volume	1,285,199	Change	-3.00%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-17-25	Initiated	BTIG Research	Buy	$21
Jan-29-24	Upgrade	Barclays	Equal Weight → Overweight	$10 → $16
Jun-23-22	Initiated	Needham	Buy	$18
May-12-22	Upgrade	Barclays	Underweight → Equal Weight	$8 → $10
Jan-20-22	Upgrade	Truist	Hold → Buy	$11
May-06-21	Upgrade	Mizuho	Neutral → Buy	$15
Apr-08-21	Reiterated	H.C. Wainwright	Buy	$20 → $22
Feb-24-21	Downgrade	Truist	Buy → Hold	$12
Jul-07-20	Downgrade	Mizuho	Buy → Neutral	$8 → $3
Feb-06-20	Resumed	Mizuho	Buy
Nov-26-19	Initiated	SVB Leerink	Outperform	$25
Sep-05-19	Resumed	Mizuho	Buy	$30
Jun-28-19	Initiated	Wells Fargo	Market Perform	$16
Jun-11-19	Initiated	Barclays	Underweight	$13
Mar-20-19	Initiated	SunTrust	Buy	$30
Feb-14-19	Initiated	H.C. Wainwright	Buy	$37
Jan-29-19	Initiated	Stifel	Buy	$27

Show Previous Ratings

May-16-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-13-25 09:51AM	Evolus, Inc. (EOLS): A Bull Case Theory (Insider Monkey)
May-08-25 09:47AM	Q1 2025 Evolus Inc Earnings Call (Thomson Reuters StreetEvents) -14.20%
03:28AM	Evolus Inc (EOLS) Q1 2025 Earnings Call Highlights: Strong Revenue Growth Amid Market Challenges (GuruFocus.com)
May-07-25 07:14PM	Evolus projects $345M-$355M revenue for 2025 with new product launches (Seeking Alpha)
07:13PM	Loading…
07:13PM	Evolus, Inc. (EOLS) Q1 2025 Earnings Call Transcript (Seeking Alpha)
06:55PM	Evolus, Inc. (EOLS) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Evolus Reports First Quarter 2025 Results (Business Wire)
May-05-25 04:05PM	Evolus Strengthens Balance Sheet with Refinancing; Reducing Cost of Capital and Expanding Financial Flexibility (Business Wire)
May-01-25 07:30AM	SNDL Inc. (SNDL) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
Apr-30-25 10:01AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Apr-23-25 08:00AM	Evolus to Report First Quarter Financial Results on May 7, 2025 (Business Wire) +7.36%
Apr-22-25 07:10PM	Evolus: Two-Product Aesthetics Company With A Competitive Edge (Seeking Alpha)
Apr-18-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-16-25 08:00AM	Evolus Announces Commercial Launch of Evolysse (Business Wire)
08:00AM	Loading…
Apr-15-25 08:00AM	Evolus Launches "Drop the F Word" Campaign in Advance of the Commercial Launch of Evolysse Injectable Hyaluronic Acid Gels (Business Wire)
Mar-25-25 08:00AM	Evolus to Participate in The Needham 24th Annual Virtual Healthcare Conference (Business Wire)
Mar-21-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-10-25 04:53PM	Mixue Group's Splashy Debut, Kroger's Change, Stuffed Crust Pizza, and Med Spas (Motley Fool) -6.63%
Mar-05-25 07:13AM	Q4 2024 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
02:09AM	Evolus Inc (EOLS) Q4 2024 Earnings Call Highlights: Record Revenue Growth and Strategic Market ... (GuruFocus.com)
Mar-04-25 05:25PM	Evolus, Inc. (EOLS) Q4 Earnings and Revenues Lag Estimates (Zacks)
04:05PM	Evolus Reports Record Fourth Quarter and Full-Year 2024 Financial Results; Reaffirms 2025 Guidance (Business Wire)
Mar-02-25 06:08PM	Is Evolus, Inc. (EOLS) the Best Small Cap Pharma Stock to Buy Now? (Insider Monkey)
Feb-27-25 08:00AM	Evolus to Participate in Fireside Chats and One-on-One Meetings at Upcoming Investor Conferences (Business Wire)
Feb-20-25 08:00AM	Evolus to Participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit (Business Wire)
Feb-18-25 08:00AM	Evolus to Report Fourth Quarter and Year End 2024 Results on March 4, 2025 (Business Wire)
Feb-14-25 08:53AM	Evolus (EOLS) Moves 5.5% Higher: Will This Strength Last? (Zacks)
Feb-13-25 01:30PM	Evolus Announces FDA Approval of Evolysse Form and Evolysse Smooth Injectable Hyaluronic Acid Gels (Business Wire) +5.47%
Feb-07-25 07:09PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:46AM	Loading…
Jan-22-25 07:46AM	Evolus (EOLS) Surges 28.3%: Is This an Indication of Further Gains? (Zacks)
Jan-21-25 04:04PM	Evolus, An AbbVie And Botox Rival, Just Hit The Stratosphere Here's Why (Investor's Business Daily) +28.26%
08:00AM	Evolus Announces Preliminary Unaudited Fourth Quarter and Full-Year 2024 Net Revenue, Achieving Record Results at the Top of the Companys Guidance (Business Wire)
Jan-17-25 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Dec-13-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-18-24 09:55AM	Here's Why Evolus (EOLS) Could be Great Choice for a Bottom Fisher (Zacks)
Nov-14-24 09:35AM	Down -29.8% in 4 Weeks, Here's Why You Should You Buy the Dip in Evolus (EOLS) (Zacks)
Nov-07-24 06:00AM	Evolus Inc (EOLS) Q3 2024 Earnings Call Highlights: Revenue Surge Amid Market Challenges (GuruFocus.com) -14.99%
Nov-06-24 06:25PM	Evolus, Inc. (EOLS) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Evolus Reports Third Quarter 2024 Results (Business Wire)
Nov-01-24 08:00AM	Evolus to Participate in Stifel 2024 Healthcare Conference (Business Wire)
Oct-31-24 02:02PM	Evolus Announces EU Approval of Estyme Injectable Hyaluronic Acid Gels Under New Medical Device Regulation (Business Wire)
Oct-30-24 10:01AM	Will Evolus, Inc. (EOLS) Report Negative Earnings Next Week? What You Should Know (Zacks)
Oct-29-24 08:00AM	Evolus Rewards Patient Loyalty Program Surpasses 1 Million Enrolled Consumers (Business Wire)
Oct-23-24 08:00AM	Evolus to Report Third Quarter Financial Results on November 6, 2024 (Business Wire)
Oct-11-24 10:53PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Oct-09-24 03:36PM	Evolus Inc (EOLS) Q2 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic Advancements (GuruFocus.com)
Sep-27-24 09:00PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-06-24 08:00AM	Evolus to Ring the Nasdaq Stock Market Closing Bell on Friday, September 13, 2024 (Business Wire)
Aug-09-24 04:30PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:39AM	Evolus, Inc. (EOLS): Is It One of Caligan Partners Top Holdings Now? (Insider Monkey)
Aug-01-24 04:00PM	Evolus, A Medical Aesthetics Player, Becomes Profitable Two Quarters Early (Investor's Business Daily) +13.04%
Jul-31-24 09:56PM	EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q2 2024 (InvestorPlace)
06:45PM	Evolus, Inc. (EOLS) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Evolus Reports Second Quarter 2024 Results and Raises Full Year Revenue Guidance (Business Wire)
08:00AM	Evolus to Hold Investor Day on September 12, 2024 (Business Wire)
Jul-30-24 08:00AM	Evolus Expands Global Footprint with Introduction of Nuceiva (botulinum toxin type A) in Australia (Business Wire)
Jul-25-24 08:00AM	Evolus to Participate in the Canaccord Genuity 44th Annual Growth Conference (Business Wire)
Jul-23-24 07:03AM	Evoluss frown line treatment Jeuveau could threaten Botox revenues (Pharmaceutical Technology)
Jul-17-24 08:00AM	Evolus to Report Second Quarter Financial Results on July 31, 2024 (Business Wire)
Jul-01-24 08:00AM	Evolus Announces Appointment of Albert G. White III to Board of Directors (Business Wire)
Jun-24-24 08:00AM	Evolus Announces Submission of Premarket Approval Application to the U.S. Food and Drug Administration for First Two Evolysse Dermal Filler Products (Business Wire)
Jun-12-24 08:00AM	Evolus Broadens International Presence with Launch of Nuceiva (botulinum toxin type A) in Spain (Business Wire)
Jun-07-24 05:00PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -5.73%
May-28-24 01:00AM	The Evolution of Medical Aesthetics and Its Growing Foothold in the Beauty Space (WWD)
May-21-24 10:57AM	Evolus (EOLS) Releases Favorable Dermal Fillers Study Data (Zacks)
May-20-24 08:30AM	Evolus Announces Positive Data from Pivotal Trial for First Two Evolysse Dermal Filler Products at 2024 SCALE Meeting (Business Wire)
May-16-24 02:54AM	Director David Gill Sells 10,361 Shares of Evolus Inc (EOLS) (GuruFocus.com)
02:54AM	Director Vikram Malik Sells 28,000 Shares of Evolus Inc (EOLS) (GuruFocus.com)
May-15-24 08:30AM	Evolus Celebrates Fifth Anniversary of Launching its Flagship Product Jeuveau at the Women's Wear Daily Beauty CEO Summit (Business Wire)
May-10-24 06:55PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
09:10AM	Evolus Sandra Beaver Named Orange County Business Journals Public Company CFO of the Year (Business Wire)
May-08-24 11:09AM	Evolus, Inc. (NASDAQ:EOLS) Q1 2024 Earnings Call Transcript (Insider Monkey)
07:24AM	Q1 2024 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
03:53AM	Evolus Inc (EOLS) (Q1 2024) Earnings Call Transcript Highlights: Strong Growth and Strategic ... (GuruFocus.com)
May-07-24 08:58PM	EOLS Stock Earnings: Evolus Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
06:35PM	Evolus, Inc. (EOLS) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
05:46PM	Evolus Inc (EOLS) Q1 2024 Earnings: Surpasses Revenue Estimates with Significant Growth (GuruFocus.com)
04:05PM	Evolus Reports First Quarter 2024 Results and Provides Business Update (Business Wire)
May-02-24 07:37AM	Today's Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday (InvestorPlace)
Apr-23-24 04:30PM	Evolus to Report First Quarter Financial Results on May 7, 2024 (Business Wire)
Apr-21-24 10:39AM	11 Best Low Price Pharma Stocks To Invest In (Insider Monkey)
Apr-17-24 04:05PM	Evolus Announces Publication of Safety and Duration Data from Phase 2 Study for Extra-Strength 40U Formulation of Jeuveau (Business Wire)
Apr-12-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-26-24 08:00AM	Evolus to Participate in the 23rd Annual Needham Virtual Healthcare Conference (Business Wire)
Mar-14-24 07:04AM	10 Stocks George Soros and Insiders Are Crazy About (Insider Monkey)
Mar-13-24 09:55AM	Does Evolus, Inc. (EOLS) Have the Potential to Rally 63.24% as Wall Street Analysts Expect? (Zacks)
Mar-11-24 07:00AM	Evolus Announces Pricing of $50.0 Million Underwritten Offering of Common Stock (Business Wire)
Mar-08-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
03:24PM	Evolus, Inc. (NASDAQ:EOLS) Q4 2023 Earnings Call Transcript (Insider Monkey)
12:30PM	Q4 2023 Evolus Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-07-24 10:34PM	Evolus Inc (EOLS) Reports Record Revenues in Q4 and Full Year 2023, Eyes Profitability in 2024 (GuruFocus.com)
09:53PM	EOLS Stock Earnings: Evolus Misses EPS, Beats Revenue for Q4 2023 (InvestorPlace)
04:05PM	Evolus Reports Record Fourth Quarter and Full Year 2023 Financial Results; Reaffirms 2024 Guidance (Business Wire)
Mar-04-24 08:28PM	11 Best Small Cap Pharma Stocks to Invest In (Insider Monkey)
Mar-01-24 08:30AM	Evolus Announces Results from European Head-to-Head Filler Trial (Business Wire)
Feb-27-24 08:30AM	Evolus to Participate in Upcoming Leerink Partners and Barclays Investor Conferences (Business Wire)
Feb-22-24 04:30PM	Evolus to Report Fourth Quarter and Year End 2023 Results and Provide Business Update on March 7, 2024 (Business Wire)
Feb-09-24 04:05PM	Evolus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-02-24 09:10PM	Evolus Inc Director Karah Parschauer Sells 11,931 Shares (GuruFocus.com) -5.20%

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Avelar Rui	See Remarks	May 12 '25	Sale	9.87	3,385	33,397	359,082	May 14 07:27 PM
Beaver Sandra	Chief Financial Officer	May 13 '25	Sale	10.02	6,494	65,070	167,089	May 14 07:27 PM
MOATAZEDI DAVID	See Remarks	May 12 '25	Sale	9.87	15,787	155,756	492,832	May 14 07:27 PM
MOATAZEDI DAVID	See Remarks	Mar 27 '25	Sale	12.40	6,251	77,512	508,619	Mar 28 06:59 PM
Avelar Rui	See Remarks	Mar 18 '25	Sale	13.26	27,904	369,868	362,467	Mar 20 06:27 PM
Beaver Sandra	Chief Financial Officer	Mar 18 '25	Sale	13.26	8,996	119,243	173,583	Mar 20 06:27 PM
Yamagishi-Dressler Tomoko	Chief Marketing Officer	Mar 18 '25	Sale	13.26	4,536	60,125	95,671	Mar 20 06:27 PM
MOATAZEDI DAVID	See Remarks	Mar 18 '25	Sale	13.26	103,376	1,370,249	514,870	Mar 20 06:27 PM
Parschauer Karah Herdman	Director	Mar 12 '25	Sale	12.99	12,888	167,465	32,183	Mar 14 05:59 PM
Parschauer Karah Herdman	Director	Mar 12 '25	Proposed Sale	12.99	12,888	167,465		Mar 12 05:55 PM
Avelar Rui	See Remarks	Dec 23 '24	Sale	10.85	2,252	24,438	366,595	Dec 26 05:28 PM
Beaver Sandra	Chief Financial Officer	Dec 23 '24	Sale	10.85	1,586	17,211	146,916	Dec 26 05:28 PM
MOATAZEDI DAVID	See Remarks	Dec 23 '24	Sale	10.85	10,502	113,967	522,847	Dec 26 05:28 PM
Beaver Sandra	Chief Financial Officer	Sep 06 '24	Sale	14.98	3,276	49,074	148,502	Sep 06 09:45 PM
Yamagishi-Dressler Tomoko	Chief Marketing Officer	Aug 30 '24	Sale	15.85	5,631	89,251	82,375	Sep 04 04:14 PM
MOATAZEDI DAVID	See Remarks	Jun 06 '24	Option Exercise	7.28	175,940	1,280,843	709,289	Jun 06 07:01 PM
MOATAZEDI DAVID	See Remarks	Jun 05 '24	Option Exercise	5.46	155,278	847,818	688,627	Jun 06 07:01 PM
MOATAZEDI DAVID	See Remarks	Jun 06 '24	Sale	12.59	175,940	2,214,486	533,349	Jun 06 07:01 PM
MOATAZEDI DAVID	See Remarks	Jun 05 '24	Sale	12.92	155,278	2,006,456	533,349	Jun 06 07:01 PM
MOATAZEDI DAVID	See Remarks	Jun 04 '24	Sale	12.73	140,214	1,784,686	533,349	Jun 06 07:01 PM
Malik Vikram	Director	Jun 03 '24	Sale	12.96	7,500	97,203	246,514	Jun 05 09:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Evolus Inc

Upgrade your FINVIZ experience